FDA’s new voucher program hints at broader policy agenda, making many ‘uncomfortable’
BioSpace
While drugmakers and other stakeholders want to see faster approvals, experts say the FDA's Commissioner's National Priority Review voucher program is still bereft of important details, with candidate
pharminent
June 19, 2026 (Last updated: June 22, 2026)
BioSpace
While drugmakers and other stakeholders want to see faster approvals, experts say the FDA’s Commissioner’s National Priority Review voucher program is still bereft of important details, with candidate